- Home
- / Sigilon
Sigilon
Revenue
$14.2 M
FY, 2019
Sigilon Summary
Company Summary
- Overview
- Sigilon Therapeutics is a biotechnology company developing functional cures for patients with chronic diseases. It develops Shielded Living Therapeutics, or SLTx, a platform that combines cell engineering with innovations in biocompatible materials and enables Sigilon's product candidates to produce a range of therapeutic molecules that may be missing or deficient.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2015
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://sigilon.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Philip Ashton-Rickardt, Chief Scientific Officer
Sarah Yuan, Chief Technical Operations Officer
Matthew Kowalsky, Chief of Staff, Chief Legal and Administrative Officer and Secretary
Operating MetricsView all
Lead Optimization Stage Products
2
Q3, 2020
IND-Enabling Stage Products
3
Q3, 2020
Phase I/II Trials Products
1
Q3, 2020
LocationsView all
1 location detected
Cambridge, MA HQ
United States
100 Binney St #600
Sigilon Financials
Summary Financials
- Revenue (FY, 2019)
- $14.2M
- Net income (FY, 2019)
- ($43.9M)
- Cash (Q3, 2020)
- $62.6M
- EBIT (FY, 2019)
- ($44.1M)